Jessica F Magidson1, Hari S Iyer2, Kristen S Regenauer3, David J Grelotti4, Janan J Dietrich5, Ingrid Courtney6, Gugu Tshabalala7, Catherine Orrell8, Glenda E Gray9, David R Bangsberg10, Ingrid T Katz11. 1. Department of Psychology, University of Maryland, College Park, 4095 Campus Drive, College Park, MD, USA. Electronic address: jmagidso@umd.edu. 2. Harvard T. H. Chan School of Public Health, 677 Huntington Avenue, Boston, MA, USA. Electronic address: hai161@mail.harvard.edu. 3. Department of Psychiatry, Massachusetts General Hospital, One Bowdoin Square, Boston, MA, USA. Electronic address: kregenauer@mgh.harvard.edu. 4. Department of Psychiatry, University of California San Diego, La Jolla, CA, USA. Electronic address: dgrelotti@ucsd.edu. 5. Perinatal HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa. Electronic address: dietrichj@phru.co.za. 6. Department of Medicine and the Institute of Infectious Disease and Molecular Medicine, Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, ZA, South Africa. Electronic address: Ingrid.Courtney@hiv-research.org.za. 7. Perinatal HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa. Electronic address: Tshabalalag@phru.co.za. 8. Department of Medicine and the Institute of Infectious Disease and Molecular Medicine, Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, ZA, South Africa. Electronic address: catherine.orrell@hiv-research.org.za. 9. Perinatal HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; Office of the President, South African Medical Research Council, Western Cape, ZA, South Africa. Electronic address: glenda.gray@mrc.ac.za. 10. Oregon Health & Science University-Portland State University School of Public Health, Portland, OR, USA. Electronic address: bangsber@ohsu.edu. 11. Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Massachusetts General Hospital Center for Global Health, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: Ikatz2@bwh.harvard.edu.
Abstract
BACKGROUND: South Africa has the highest number of people living with HIV (PLWH) and one of the largest antiretroviral therapy (ART) programs globally. High rates of substance use comorbidity exist, including speculation of recreational ART use (i.e., mixing ART with other illicit drugs). Recreational ART use may affect viral load among PLWH due to ART nonadherence and/or viral resistance; however, prior quantitative research has not examined rates of recreational ART use, nor associations with HIV treatment outcomes longitudinally. METHODS: Data were drawn from a prospective, observational cohort study (n = 500) of ART-eligible adults recruited from two HIV voluntary counseling and testing centers in Cape Town, and Johannesburg, South Africa. Multiple logistic regression models assessed recreational ART use as a predictor of ART initiation over six months and viral load suppression over nine months, above and beyond other substance use (binge drinking and illicit drug use). RESULTS: Approximately 5% (n = 24) reported recreational ART use, which was less frequent in Cape Town compared to Johannesburg (AOR = 0.025; 95%CI: 0.003-0.19; p < 0.001). Recreational ART use was not significantly associated with ART initiation or viral suppression. Other substance use, but not recreational ART use, was significantly associated with lower odds of ART initiation (AOR = 0.54; 95%CI: 0.33-0.87; p = .01) and viral suppression (AOR = 0.47; 95%CI: 0.25-0.89; p = .02). CONCLUSIONS: Recreational ART use was infrequent and not uniquely associated with ART initiation or viral suppression. Findings suggest that comorbid use of other substances is ultimately what may make recreational ART use problematic for ongoing engagement in care and viral suppression.
BACKGROUND: South Africa has the highest number of people living with HIV (PLWH) and one of the largest antiretroviral therapy (ART) programs globally. High rates of substance use comorbidity exist, including speculation of recreational ART use (i.e., mixing ART with other illicit drugs). Recreational ART use may affect viral load among PLWH due to ART nonadherence and/or viral resistance; however, prior quantitative research has not examined rates of recreational ART use, nor associations with HIV treatment outcomes longitudinally. METHODS: Data were drawn from a prospective, observational cohort study (n = 500) of ART-eligible adults recruited from two HIV voluntary counseling and testing centers in Cape Town, and Johannesburg, South Africa. Multiple logistic regression models assessed recreational ART use as a predictor of ART initiation over six months and viral load suppression over nine months, above and beyond other substance use (binge drinking and illicit drug use). RESULTS: Approximately 5% (n = 24) reported recreational ART use, which was less frequent in Cape Town compared to Johannesburg (AOR = 0.025; 95%CI: 0.003-0.19; p < 0.001). Recreational ART use was not significantly associated with ART initiation or viral suppression. Other substance use, but not recreational ART use, was significantly associated with lower odds of ART initiation (AOR = 0.54; 95%CI: 0.33-0.87; p = .01) and viral suppression (AOR = 0.47; 95%CI: 0.25-0.89; p = .02). CONCLUSIONS: Recreational ART use was infrequent and not uniquely associated with ART initiation or viral suppression. Findings suggest that comorbid use of other substances is ultimately what may make recreational ART use problematic for ongoing engagement in care and viral suppression.
Authors: Matthew P Fox; Mhairi Maskew; A Patrick MacPhail; Lawrence Long; Alana T Brennan; Daniel Westreich; William B MacLeod; Pappie Majuba; Ian M Sanne Journal: Int J Epidemiol Date: 2012-03-20 Impact factor: 7.196
Authors: David J Grelotti; Elizabeth F Closson; Jennifer A Smit; Zonke Mabude; Lynn T Matthews; Steven A Safren; David R Bangsberg; Matthew J Mimiaga Journal: AIDS Behav Date: 2014-03
Authors: Jessica F Magidson; John A Joska; Kristen S Regenauer; Emily Satinsky; Lena S Andersen; C J Seitz-Brown; Christina P C Borba; Steven A Safren; Bronwyn Myers Journal: Int J Drug Policy Date: 2019-05-10
Authors: Kevin D Shield; Margaret Rylett; Gerhard Gmel; Gerrit Gmel; Tara A K Kehoe-Chan; Jürgen Rehm Journal: Addiction Date: 2013-03-04 Impact factor: 6.526
Authors: Kathryn Rough; Janan Dietrich; Thandekile Essien; David J Grelotti; David R Bansberg; Glenda Gray; Ingrid T Katz Journal: AIDS Behav Date: 2014-07
Authors: Bronwyn Myers; John A Joska; Crick Lund; Naomi S Levitt; Christopher C Butler; Tracey Naledi; Peter Milligan; Dan J Stein; Katherine Sorsdahl Journal: Patient Prefer Adherence Date: 2018-09-18 Impact factor: 2.711
Authors: Mhairi Maskew; Jacob Bor; Cheryl Hendrickson; William MacLeod; Till Bärnighausen; Deenan Pillay; Ian Sanne; Sergio Carmona; Wendy Stevens; Matthew P Fox Journal: BMC Health Serv Res Date: 2017-01-17 Impact factor: 2.908
Authors: Jessica F Magidson; John A Joska; Bronwyn Myers; Jennifer M Belus; Kristen S Regenauer; Lena S Andersen; Sybil Majokweni; Conall O'Cleirigh; Steven A Safren Journal: Implement Sci Commun Date: 2020-03-04
Authors: Emmanuel Peprah; Bronwyn Myers; Andre-Pascal Kengne; Nasheeta Peer; Omar El-Shahawy; Temitope Ojo; Barbara Mukasa; Oliver Ezechi; Juliet Iwelunmor; Nessa Ryan; Fatoumata Sakho; John Patena; Joyce Gyamfi Journal: Int J Environ Res Public Health Date: 2022-01-19 Impact factor: 3.390